Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

November 8, 2023

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 81 min

Earnings Call Speaker Segments

Operator

operator
#1

Thank you for holding, everyone. I'd like to welcome you to the conference call for investors and analysts that Bayer is hosting on our results for the third quarter of 2023. During today's recorded presentation, everyone joining will be in listen-only mode. After the presentation, there will be a Q&A session. Should anyone have trouble hearing the conference, you can press the star key and then zero on your telephone to reach an operator for assistance. At this point I'll hand the conference over to Jost Reinhard, who heads Investor Relations at Bayer AG. Sir, the floor is yours.

Jost Reinhard

executive
#2

Thanks so much, Alice. Good afternoon, good morning, everyone, and a very warm welcome to our conference call covering the quarterly earnings 2023. I'm Jost Reinhard, and this is the first time I have the pleasure of being here in the role of new head of Investor Relations for Bayer. Thank you for joining the call, and I'm looking forward to working with you and connecting with you going forward. For today's presentation, Bill will get us started, and after that Rodrigo, Stefan, and Heiko will delve into the divisional. Wolfgang will then present the financial performance for Q3 and the outlook for the year, followed by Rodrigo, Stefan, and Heiko, who will dive into the divisional performances and their outlook for the divisions. After that, Bill will share an update on our strategic review and the progress already made in the last 90 days. Following from there, we will have the Q&A. I'd like to begin by drawing your attention to the cautionary language that is included in our safe harbor statement, as well as in all the materials that we have distributed today. With that, I hand over to you, Bill.

Bill Anderson

executive
#3

Okay, thank you so much, Jost, and I appreciate everyone being on the call. You've all had a chance to look at the Q3 results we released earlier today, and those results largely matched what we anticipated, given that we're well aware Q3 has never been our strongest quarter. The key takeaway here is that, based on our current position and what we're seeing for the quarter that remains, we are reaffirming the updated 2023 guidance we provided to you back in July. We recognize that a strong fourth quarter is still going to be necessary, and our focus is on delivering precisely that. And I believe the team is very confident about our outlook. So with that said, let me pass things to Wolfgang for more detail on the numbers, and later in the call he can share more on our — or rather, I'll share more on our strategic direction. Wolfgang, over to you.

Wolfgang Nickl

executive
#4

Thanks, Bill, and greetings from me as well. We’ll start by reviewing the results for our third quarter. Q3 represents our smallest quarter in terms of both sales and earnings, mainly because of the crop science business cycle. Adjusted for currency and portfolio effects, sales were level with the prior year. As reported, though, we recorded a decline of 8%, hit by portfolio effects from the divestment of our Environmental Science Professional business and further pharma divestments. The larger impact, however, came from foreign exchange rates. The top line across all three divisions felt substantial FX headwinds, totaling roughly EUR 740 million on group sales in Q3 alone, and EUR 1.2 billion across the first nine months of 2023. On the bottom line, FX effects were less pronounced. Even so, we saw an adverse impact of approximately EUR 150 million there as well for the first nine months of the year. Our EBITDA before special items reached EUR 1.7 billion, which is 31%, or around EUR 770 million, under the prior year quarter. The bulk of that decrease stemmed from our crop science business, affected by lower pricing for our glyphosate-based products and continuing elevated cost of goods sold, primarily in our crop protection business too.

Wolfgang Nickl

executive
#5

I should note that, given how the business performed, we’re seeing meaningfully lower expense from short-term incentive provisions this year. With lower earnings, core earnings per share came to EUR 0.38 in Q3, which is EUR 0.75 under the prior year. Our core tax rate of 48% was especially high in the third quarter, reflecting one-time effects against comparably low pre-tax income. In absolute terms, core taxes were lower than the prior year. For the full year, we still expect a core tax rate of around 23%, as previously guided. Reported earnings per share came in at minus four euros and sixty-six cents in Q3, as you can see in the appendix of the deck. That delta is largely driven by non-cash relevant impairment losses of approximately EUR 4 billion in our Crop Science division, which were entirely triggered by higher capital market interest rates and therefore a higher weighted average cost of capital. Our free cash flow came in at EUR 1.6 billion, in line with the crop business cycle and our forecast for the second half of this year. The positive cash flow contributed to a reduction net financial debt to about EUR 38.7 billion at the end of Q3, and this was partially offset by negative FX effects.

Wolfgang Nickl

executive
#6

I'll turn now to the outlook for the entire year. At constant currencies, we're reaffirming the guidance for the full year that we revised late in July and then confirmed in August of this year. For the third quarter, crop science performed as we had expected, and we still expect strong momentum in quarter four across our business, especially in LATAM. Within pharma, headwinds in China proved greater than we first assumed, yet we're confident we'll stay within the parameters we guided earlier. Consumer health, too, continues to track as planned. We still estimate a foreign exchange headwind to sales of roughly EUR 1.7 billion, and for EBITDA before special items, we now anticipate an FX headwind of about EUR 200 million for the full year, calculated on September month-end spot rates. As for all the remaining KPIs, FX impact isn't material according to our latest estimates. Given the third-quarter results we've delivered and our actions and projections for Q4, we're confident of meeting our full-year guidance. As we look toward next year, we have to recognize that certain market dynamics, our portfolio, and a number of our underlying assumptions have shifted materially since we last set out 2024 targets back in 2021.

Wolfgang Nickl

executive
#7

Given where the market stands right now and what we've learned so far, we're anticipating a tough 2024. Our growth prospects will probably stay weak, and we anticipate that profitability will keep facing headwinds. Within Crop Science, reference pricing for generic glyphosate has returned to levels seen historically, and we're seeing a softer market for corn commodities as we head into next year. On the pharma side, pricing and reimbursement in key markets are still under pressure. Even as we keep pushing our launches and innovation forward, we anticipate that substantial negative mix effects will persist. We also anticipate that inflationary pressure will stay elevated across all three businesses, above where it stood before the pandemic. Ongoing cost savings and price increases, wherever we can make them, are partly offsetting these effects. Taking forward rates into account, we anticipate FX will act as a headwind to sales and earnings next year. The financial result will probably take a hit from higher interest rates. Those are merely a few of the factors we're weighing carefully in our financial discussions, which are happening right now. Guidance for 2024 will come during our full-year earnings call in March. With that, Rodrigo, I'll turn it over to you to take us through Crop Science's performance last quarter and the outlook.

Rodrigo Santos

executive
#8

Thank you, Wolfgang, and thank you all for being with us today. During what is invariably our weakest quarter of the year, the third, Crop Science revenue performed a bit above our expectations, rising 1% when measured on a currency- and portfolio-adjusted basis. That figure reflected the combined result of 9% revenue growth in our core business alongside a 23% drop in sales of herbicides based on glyphosate. The upshot was the near zero EBITDA before special items that we had anticipated, as persistently elevated costs and softer glyphosate pricing more than offset core pricing, favorable currency effects, and our continuing efficiency efforts. Turning to how each business entity performed in Q3, we recorded double-digit % revenue growth in corn and in soybeans alike, driven by stronger corn prices worldwide and by increased licensing income from soybeans in Brazil. We likewise witnessed the volume rebound we had expected in crop protection, most notably in fungicides across Latin, and in glyphosate as well, where shipment volumes have been exceptionally robust since we reset prices. Given that momentum, we feel confident about delivering our full-year guidance, under which we still anticipate 5%-7% revenue growth in the core business as glyphosate sales return to normal levels. Each region is adding solidly to our core growth, and corn together with fungicides are the standouts, posting double-digit percentage revenue growth for the year.

Rodrigo Santos

executive
#9

We’re set for a third consecutive year of solid sales growth in our core business — over 10% in 2021, 6% in 2022, and now 5%-7% in 2023. On top of that, we remain on track for a 21% EBITDA margin before special items. Our confidence in the Q4 outlook rests on the continued strong rebound in LatAm crop protection, where we’ve kept a disciplined approach to managing inventories in our retail partner channel, along with global cost savings and lower short-term incentive expense — and that also drives the expected year-over-year EBITDA growth in the fourth quarter. To give you the transparency you asked for, we’re still disclosing sales of the glyphosate-based herbicide Cephory. As this slide shows, we expect 2023 sales to normalize back near 2020 levels after the Chinese generic reference price reverted to its 15-year median, notwithstanding a brief modest uptick in July. Going forward, you should assume that median price will serve as the baseline for our planning. Beyond what Wolfgang outlined, let’s consider a few more variables for 2024. An improvement in the U.S. corn stocks-to-use ratio and the associated softer commodity pricing could mean 4 to 5 million fewer planted corn acres in the U.S.

Rodrigo Santos

executive
#10

Moving into next year, the conflict in Ukraine is still ongoing, which is further reducing corn acreage as well as demand for crop inputs in that region. At the same time, in APAC, Australia is indicating reduced planted corn acreage for next season in what is a high-value market for us. In addition, recent announcements have made it clear that channel inventory levels for crop protection among our peers have been elevated, which is driving lower crop protection pricing industry-wide as they destock. And many expect that to continue into the new year. The good news is that our own channel inventories are in good shape, and we anticipate volume growth in crop protection next year as well. Lastly, like many others in the industry, we are still working through our higher-cost crop protection inventory and continue to expect elevated costs through most of next year. While these dynamics can be daunting, given our track record of innovation and operational excellence, we are well-positioned to effectively manage them and to continue delivering our vision for regenerative agriculture. On that note, I was particularly pleased to see this leadership recognized through a recent upgrade in our ISS ESG rating in the World Benchmarking Alliance ranks in the Food and Agriculture and Nature and Biodiversity.

Rodrigo Santos

executive
#11

With that said, I'll hand things over to you, Stefan.

Stefan Oelrich

executive
#12

Thank you, Rodrigo, and hello to everyone listening as well. Sales at our pharma division, adjusted for currency and portfolio effects, matched the prior year's Q3, as somewhat higher volumes were counterbalanced by pricing pressures. Regionally, North America posted 2.9% growth, and the division's prescription medicines in the U.S. did especially well, delivering a double-digit percentage increase in sales. By contrast, unfortunately, China sales fell by a double-digit percentage on a currency and portfolio-adjusted basis. This was partly attributable to a substantial reduction in hospital activity and sales rep interactions throughout the country, brought about by the anti-corruption campaign that began roughly three months ago. Added pressure is also coming from developments in franchises covered by China's volume-based procurement program, Adalat and Xarelto in particular. For the second half of 2023, we anticipate these sales headwinds could total approximately EUR 200 million and carry over into next year, affecting our launches' performance as well. Turning to profitability, the Q3 EBITDA margin before special items was 31.7%, matching the prior year and consistent with our guidance of quarter-on-quarter improvement, as we successfully offset unfavorable product mix effects and continuing R&D commitments through reduced marketing spend.

Stefan Oelrich

executive
#13

Taking a closer look at our franchises, we again saw strong performance from our launch assets Corvidia and Nubeqa, as well as from EYLEA and the radiology business, which offset headwinds across large parts of our mature portfolio — headwinds tied mostly to the China softness I mentioned to you a moment ago. On Xarelto, we were pleased with solid volume growth in certain regions during this year's third quarter. Do bear in mind, though, that patent expirations for this medicine will keep rolling out in further regions — Canada this month, and Japan by mid of next year in its major indication. And while we feel confident about the strength of our European patent covering Xarelto's once-daily intake, which expires in January 2026, we are still seeing generic manufacturers attempt to challenge our existing market exclusivity. So we cannot rule out generics launching earlier, though naturally we will take vigorous action against any patent infringement and defend our intellectual property. Q3 2023 was, I'd say, a content-rich quarter in pharma. Within our cardiovascular franchise, additional phase III studies have been started for Corvidia and for asundexian to complement the existing study programs. At the early stage, we further progressed the replenishment of our pipeline with highly innovative therapeutic approaches from our platform companies, including BlueRock's cell therapy bemdaneprocel moving into phase II next year.

Stefan Oelrich

executive
#14

On the oncology side, we moved the second drug candidate from Vividion's distinctive chemoproteomics platform into clinical testing. We began a phase I trial looking at a novel targeted alpha therapy for prostate cancer, and we also shared encouraging phase I results for a novel tyrosine kinase inhibitor aimed at HER2 and EGFR activating mutations in non-small cell lung cancer. Looking ahead, as slide 15 shows, we anticipate a series of additional pipeline catalysts arriving across the coming couple of quarters, spanning early through late stage and covering all of our therapeutic focus areas. Among these will be phase III readouts for asundexian, darolutamide, and finerenone, along with possible submissions and label expansions, readouts and launches of various cell and gene therapy trials in phase I and II, plus the launch of one more phase I program built on targeted radiotherapies, and the third phase I program from Vividion, to name just a few. Meanwhile, we also expect to see movement on the commercial front of our pipeline, with the first approvals of EYLEA 8 mg in our territories arriving very soon. So thanks for listening, and that wraps up my portion of the presentation. I'll hand things over to you, Heiko.

Heiko Schipper

executive
#15

Thanks, Stefan. I'm glad to take you through how consumer health performed and what drove things during the quarter just ended. Sales rose 2% on a CPA basis amid a competitive market that remains ongoing, with different factors at play in each region. EMEA and LATAM continued to show strong double-digit growth fundamentals, whereas North America posted a slower sales result. What we're seeing is customers bringing inventories down to lower levels, reflecting supply chain improvement after COVID as well as an environment of rising interest rates and inflation that stays elevated. In Asia Pacific, demand for nutritionals normalized further, hit in particular by falling birth rates in China, which affects our maternal product portfolio. On a very positive note, we succeeded in raising our EBITDA margin before special items by 50 basis points versus the prior year, prior year. That came even with strong headwinds from currency and inflation that remains sticky. It shows consumers still recognize the added value of our iconic brands and innovation, and it confirms our confidence in hitting our full year ambition for growth of around 5% and profitability at around 23%. At the category level, dermatology — with a strong contribution from our Bepanthen and Canesten brand families — and cough and cold grew across every region, while pain and cardio grew particularly strongly in Latin America.

Heiko Schipper

executive
#16

Nutritionals demand came back to normal after being elevated for the reasons we mentioned earlier in China. In allergy specifically, we're seeing a generally milder allergy season this year, while Astepro keeps picking up market share in the U.S. That growth is happening even with ongoing supply constraints, which hit our digestive health category in EMEA especially hard. We're steadily improving the supply situation, and while it still caps our volume growth, our strategic pricing efforts let us offset the impact of supply and sticky inflation. Overall, we're optimistic that supply will improve further in Q4, which we expect to drive faster growth in our digestive health category and lend support to the rest of our portfolio. On the bottom line, we delivered a margin of 22.2 in Q3, bringing the margin to 23.1 for the first nine months of 2023, and that's very much in line with our full year guidance of around 23%. We're executing diligently on our operational productivity programs and staying active on pricing management. That allows us to invest more behind our innovative brands and to offset inflation-related cost increases and negative currency effects. Going forward, this performance keeps us on track to meet our 2023 targets and profitability guidance as well.

Heiko Schipper

executive
#17

As I said earlier, the market conditions we operate in matter, and the digital transformation stands out as one field growing increasingly significant. Within Consumer Health, this shows up mainly in four core areas. Over recent years, we acted quickly to move our media into digital channels, boost our data-driven marketing spend, and tailor creative content for our brands. That produced a substantial rise in consumer engagement, greater marketing efficiency, and a better return on the money we put into marketing, making sure the right content reaches the right consumer at the right moment. We are also continuing to speed up our e-commerce footprint, having multiplied our online sales by four since 2019 and bought new businesses, which made e-commerce a key sales driver — it is now above 13% and we expect it to keep growing. What is more, through the partnership agreement we recently signed with Mahana Therapeutics to co-commercialize digital therapeutics, we will bring out products that let people exercise more control over their own health, personal health, via world-leading digital solutions. This ranks among the first big investments made by any global consumer health company in this space. On top of that, digital is assisting us in creating a high-performing product supply ecosystem using an agile, end-to-end planning method. AI, machine learning, and automation via predictive business steering assist us in bringing together commercial, operational, and financial planning, generating value across various business dimensions, and in the end helping us serve our customers and consumers better.

Heiko Schipper

executive
#18

So with that, I appreciate everyone listening, and I'll hand things back over to you, Bill.

Bill Anderson

executive
#19

Thanks, Heiko. Now, it goes without saying that in spite of some of the excellent developments you've heard about, this year's performance leaves us dissatisfied. Revenue of nearly EUR 50 billion paired with zero cash flow is simply unacceptable, and so is the path our share price has taken. For Bayer, then, keeping things as they are is simply not an option, and I've discussed this with many of you. We all share the view that no quick fix exists for the many challenges Bayer faces. Our commitment is to the fastest route toward creating value. This matters a great deal. You know, when we last spoke, I said every option was on the table, and since then our conversations have moved forward. So we're taking a close look at our structural options. An expert team that includes external financial advisors is in place, and we're assessing every one of them. They're examining market conditions and what structural changes would mean for our value creation, for one-time costs, dissynergies, for cash flow and leverage ratios, tax leakage, and other criteria. In this analysis, we have the full backing of every member of Bayer's Supervisory Board. We're not tied to any single structure, and we're going to follow the best path to ensure maximum value creation, and fast.

Bill Anderson

executive
#20

Naturally, we've examined our strategy and operating model closely to determine how Bayer's strong asset base can deliver more, and I'll elaborate on that shortly. On the structural front, apart from keeping three divisions, the principal alternatives would involve separating either Consumer Health or Crop Science, and both are still being evaluated. We keep assessing those seriously and transparently. Some options have also been removed from consideration. For instance, we looked at splitting the company into three businesses at the same time. That option is being ruled out. Doing it all at once simply isn't feasible. A three-way split would need a two-step process. And we certainly won't pursue any structural moves that would carry a downgrade of our operational performance. So Bayer's problems must be tackled at the core. That's why we're acting decisively in a manner that doesn't restrict our options base. So this year, we have zero cash flow projection, and whether you divide 0 by 2 or divide 0 by 3, it's still 0, okay? So that's why we must act decisively and move forward, now. So we will regularly evaluate the company on our mission delivery, on our speed, our return on innovation, and our performance against peers.

Bill Anderson

executive
#21

We've already begun taking some fairly decisive steps that will expand the options available to us. The rationale for deep-seated change is unmistakable. Every Bayer employee sees that clearly. Over the past 90 days I've held hundreds of conversations on this, and by and large, everyone is on the same page. Action is needed, and it's needed right away. So this is what we're doing. First, we will concentrate everything on the mission. Second, we are pushing innovation. And third, we intend to boost performance. I'll walk through each of those in turn. To start, let me explain what concentrating on the mission involves. Bayer has businesses that, individually and as a group, hold a vital place, a vital role in the world. Health for All, Hunger for None captures that really well. Unfortunately, that hasn't consistently been at the forefront of how we operate, and that has to change. We're reshaping Bayer so it focuses solely on what is essential to our mission, and then discarding all the rest. That calls for a new operating system. We refer to it as Dynamic Shared Ownership, and it amounts to a radical realignment of how a multinational company runs. At most companies, management layers spend months on items such as budgeting processes, performance reviews, target setting.

Bill Anderson

executive
#22

Incidentally, not one of those things benefits the customer, and Bayer isn’t an exception either. A countless quantity of time and energy from extremely intelligent individuals gets poured into our yearly forecasts, budgets, and targets, along with everything that accompanies them. In spite of all this, naturally, we reduced the initial targets we had set for 2023. That is a grave matter, and we are dealing with it. Dynamic Shared Ownership relocates the center of gravity away from internal processes, which are hierarchically aligned, toward the needs of the people we serve. This will bring decision-making considerably nearer to customers, and it will move our emphasis from planning toward action. This is going to affect every role, every process, every activity across the company. Going forward, practically everybody at the company will operate within small, self-managed teams centered on a customer or a product, much as small business owners would. Anything off mission must be eliminated, and we will track progress through swift 90-day cycles that translate into far quicker customer response and product innovation. Lastly, this approach also delivers a substantial cost reduction, since you simply do not require much of the management and coordination work that big companies have split into thousands of boxes on org charts over decades.

Bill Anderson

executive
#23

A lot of those specialized coordination jobs are not going to survive as standalone positions. That work is going to get folded into what a team is responsible for. I've witnessed this pattern before. It truly frees up the complete energy, the pace, the dedication of our workforce in a really powerful manner. Let me be clear: this isn't mere restructuring. Bayer has been through plenty of that already. In plain restructuring, after all, you take an org chart showing 500 boxes and you eliminate 50 of them, yet fundamentally nothing shifts. According to our employee survey, 90% of our people feel a great deal of pride about working for a company with a mission like ours — 90% — yet merely 10% think our present setup permits decisions to be made at the proper level. I have to wonder whether that 10% is the group that actually gets to decide things. That's simple to grasp, isn't it? Over the last six years, the company has launched multiple conventional cost-reduction initiatives. In fact, we remain in the middle of one at this moment. I mean, those projects were undertaken with the finest intentions, but as frequently happens, the outcomes have not appeared on the bottom line in a lasting fashion. Even after many reorganizations, the count of senior leaders has stayed unchanged.

Bill Anderson

executive
#24

Roughly 12 layers still sit between me and the customers. That is just too many, and this is not about pinching pennies. It is a completely different mode of operation, moving away from a static command and control setup toward one in which customer needs sit at the center of everything. Come the end of 2024, Bayer will strip out several layers of management and coordination, and that move is going to free our teams with the mission focus required to reverse the situation. The yardstick is straightforward: 95% of decisions across the entire organization are going to land with the people doing the work. Over the past 90 days, we have already begun. Some examples follow. We have changed leadership in our human resources and transformation area, and in the strategy and investor relations teams. We are putting a number of further changes in place at senior levels. We have also merged our impact investment arm, Leaps, into our Pharma Business Development and Licensing unit. Each of our three businesses has drawn up plans to overhaul its commercial models. That is remarkable. All three divisions, within that window of time, reworking how they engage with customers so the impact is much clearer and stronger. We are already rolling out the first of these systems in test markets right now.

Bill Anderson

executive
#25

As of now, we have deployed the system to 2,500 Bayer employees, right? We began at 0 in July, and come 2024, it will reach the whole organization. This represents a deep transformation, and we are eliminating a great deal of work, which will involve a substantial decrease in the workforce. Since we last spoke, I have been communicating regularly with our employee representatives. In this system change, they are a highly valuable and supportive partner, and I appreciate their trust and the ongoing dialogue as we work out the best path ahead. My full expectation is that the outcome will be more meaningful jobs, correct? These are roles where individuals have the freedom to act like an owner, and we will, we will make those jobs more meaningful, deliver more innovation for our customers, and achieve better performance for shareholders. So we also expect significant and sustainable savings. We will provide the details at Capital Markets Day in March 2024. Our second priority is pushing innovation forward. We are intensifying our focus on everything that fuels growth, and we are drastically simplifying everything that does not. Upon joining the company, I noticed two things very quickly and very clearly. The first was a broad landscape of administration and controls. The second is enormous innovation potential.

Bill Anderson

executive
#26

Let me illustrate what I mean by administrative controls. The company maintains 1,362 pages of central rules and regulations specific to Bayer. They even have a special name for it, okay? And seriously, we have resources dedicated to promulgating these 1,300 pages of rules all around the world to every Bayer employee. Well, we're gonna consolidate that dramatically. We're gonna reduce it by 99%. I already mentioned the countless hours spent on forecasting and planning. We're streamlining that process. We're aiming for something like an 80% reduction in the amount of time that leaders and people of Bayer are spending on planning, forecasting, target setting. All of that energy is gonna be redirected to getting the most out of the company's great assets. We have products in the market with good momentum, like Nubeqa and Pharma or the Intacta 2 Xtend soybeans and crop science. We have great things in the pipeline. We have the Preceon Smart Corn System, which is expected to launch next season in the U.S. Consumer Health continues to advance personalized health offerings. In the past 90 days, we've expanded our phase III programs behind Kerendia and asundexian, as you heard from Stefan, and our Consumer Health division continues to pursue differentiated Rx-to-OTC switches, where our scientific capabilities are a big advantage.

Bill Anderson

executive
#27

That's only a portion of what we're innovating at Bayer, and it's what we're focused on delivering. Bringing greater product centricity into our R&D model is going to let us deliver innovation faster and more productively. Last, a few words on strengthening performance. Bureaucracy at Bayer doesn't only weigh on people's time. Naturally, it impacts results. Just as we're simplifying how the organization focuses on the mission, we're going to simplify incentives. The Supervisory Board will put forward a proposal to the 2024 shareholders meeting for approval, aligning our remuneration more closely with what matters for our mission and what matters to you. Here are some initial details: the Supervisory Board is working on a remuneration package under which the Management Board and I will be assessed against a clear, transparent set of financial and sustainability KPIs. Previously, 40% of our long-term incentive was adjusted by the way our share price performed. Going forward, the proposal aims to double that figure to 80%. I expect sustainable growth and free cash flow are also of importance. Free cash flow, particularly relevant given our anemic performance this year, and the proposal measures our cash performance not on cash flow without litigation, but on cash flow as reported.

Bill Anderson

executive
#28

The complete particulars on this will be laid out before the 2024 AGM, and we'll also test the waters with investors in the period until then. So that gives you a 90-day view of where we stand. We're only at the beginning, yet we're progressing quickly and carefully. I've been in this position previously, and the payoff is certainly worth it. All of these steps together will produce an organization entirely fired up to deliver consistently stronger performance. Everyone I speak with at Bayer recognizes the need for change — for major change — and our people are enthusiastic about what we're doing here. That shared commitment is powerful. It's among the many reasons I'm confident we will succeed. We aim to generate sustainable value for all stakeholders. It's going to look dramatically different from how it has in the past, and there's no time to waste. In March of next year, we're going to combine our full year earnings call with a capital markets day. The agenda is straightforward. It's about delivering the best version of this company with the most speed, the least risk, and the best return. In the weeks ahead, I'm going to seek conversations with many of you about our plans, and I want to thank you in advance for your contributions.

Bill Anderson

executive
#29

Appreciate it once more, and I’m looking forward to taking your questions.

Jost Reinhard

executive
#30

Thanks a lot, Bill, and thanks to every one of the presenters. So with that, we'll go ahead and move on to Q&A. Just a quick reminder, please, to limit yourselves to two questions so that we're able to fit in as many participants as possible. Alice, would you please open up the line for questions.

Operator

operator
#31

Thank you. Ladies and gentlemen, we're going to start the question-and-answer portion now. Should you have a question, kindly press the star key and then the one on your phone. To withdraw your request, press the star followed by the two. Today, if you're on speaker equipment, please pick up the handset before making your selections. Please hold a moment for the first question. Our first question is from Peter Verdult at Citi. Please go ahead.

Peter Verdult

analyst
#32

Thank you. Peter Verdult from Citi. I have plenty of questions, but I'll keep myself in check and limit it to 2. First shot, for Wolfgang or Bill. You left the door open for 2024 with some qualitative remarks about growth and profitability. If I may push my luck and go through a few of the vectors you laid out in the presentation slides, it looks like, you know, in the best case, EBITDA would be flat next year, with core EPS just barely above EUR 5 once higher financial charges and possible tax rate increases are factored in. Now, I understand this isn't the venue for official 2024 guidance, but since you've opened that door and given the kind of incoming I've had from investors today, any assistance you could give to dimensionalize that would be helpful. Then, more simply, Wolfgang, my second question is on the dividend — is there any risk there? Is there a commitment? Given the balance sheet and the need to refinance, what is the state of the dividend? Thank you.

Wolfgang Nickl

executive
#33

Okay, Pete and Wolfgang — I'll kick things off here. Let's begin with the dividend. My stance matches the one I shared together with my colleagues back in August. There's a policy in place, and under that policy we distribute a dividend equal to between 30% and 40% of core EPS. As things stand at the moment, that's exactly what we intend to carry out. Sure, free cash flow this year comes to zero, but we fully intend to make next year look very different, even with the softer top line and softer profitability we likely face. There are plenty of other levers on the cash flow, working capital, and CapEx fronts to achieve that. I could also rewind to 2024 and pass things to Bill, if you'd like to chime in. But I'm afraid we've gone as far as we're comfortable going right now in offering you some vectors, since we've likewise looked at the consensus for next year, and we thought it important to flag that growth is somewhat softer. I've explained the reasons. You've heard my colleague Rodrigo discuss it for Crop, and you've heard Stefan address it in Pharma.

Wolfgang Nickl

executive
#34

And it's also fairly evident that where costs are concerned, inflation—much as we'd like it to—isn't disappearing. You witnessed a soft free cash flow this year. As you'd expect, part of that inflation therefore remains in inventory and will impact the P&L next year. I think you're quite aware of what's occurring with interest rates, and we aren't shielded from it. You've watched us refinance. You track the forward rates on FX. Just 80% of our business sits in the Eurozone. We conduct considerable business in developing markets. All of that feeds into that calculation. I'm fairly certain many people on this call would prefer far more numerical guidance there, but right now, I think we must leave that to the vectors as my colleagues and I have described them.

Peter Verdult

analyst
#35

Got it. Thanks.

Bill Anderson

executive
#36

Yes. Thank you, Wolfgang. Let me just add that, I believe all of us — and I speak on behalf of every member of the board of management — feel very optimistic regarding Bayer's future, and the innovations we're delivering excite us. The pipeline in Crop, you know, has never appeared this strong, and we see, for instance, the launch of short-stature corn next year as one of agriculture's next truly major milestones. In Pharma, we're enthusiastic about the strides we've been making on the pipeline. Still, the fact is that in 2024 we face some headwinds, whether from interest rates or FX or, you know, we begin to see Xarelto erode this year, and we expect that to speed up next year. There's, I think, everyone asking questions about the agriculture cycle, and we have to let that play out. So I think we're, yes, we're quite positive about the future, about what we can accomplish internally and the long-term outlook for our businesses. But 2024 is challenging. Still, we can, yeah, if we can get to the next question. Thanks.

Operator

operator
#37

Our following question is from Sachin Jain at Bank of America. Go ahead, please.

Sachin Jain

analyst
#38

Hello, and thanks for taking my questions. I have two — one on finances, then one on strategy. On the financial side for 2024, Stefan, I was somewhat surprised that you mentioned the Xarelto situation in Europe. Could you give us a bit more detail on that and explain how you view the likelihood of at-risk generic launches? I just want clarity on whether the European Xarelto risk is included in the 2024 outlook that Wolfgang and Bill provided. And if you could also remind me, I believe Japan plus the major European countries account for roughly 30% of Xarelto sales — just to verify that. Then my second question is for Bill. Some media commentary suggested that anything you might do from a structural standpoint could take around five years. So could you clarify that? Whatever decision you announce in March, what is the path after that which takes so long? Thank you.

Bill Anderson

executive
#39

Sure. Let’s see here. Stefan, would you like to say something about Xarelto?

Stefan Oelrich

executive
#40

Okay, and thanks for asking that, Sachin. Let me lay out where things stand. As you're aware, in Europe we hold the use patent covering the oral hourly dose tablet through 2026. At present, what we're encountering is essentially disputes in every country. We've consistently stated this outcome was coming and that we'd have to defend it market by market. Thus far, the Netherlands is one place where we prevailed at first instance. Norway is another, with a first-instance win for us. Australia too — we won at first instance there on the patent. Even so, essentially every remaining country still has to be worked through. On top of that, we've also seen once-daily capsules of rivaroxaban filed in a number of countries. Those products will attempt to go around our patent, so we'll need to contest them in court, and while we have confidence in the IP, that's the position: this is going to come down to litigation.

Bill Anderson

executive
#41

And Sachin, I think, regarding our outlook, we, as always, operate in an industry where ambiguity comes from many places — whether that's product development, IP, or, you know, defending patents. So on most things we tend to adopt views that are probability adjusted, and I think that's a fair assumption to make. Then I think the other question — how long structural moves would take — probably there might be a bit of confusion around that. This morning, in the media interviews, someone asked me what the process looks like for these structural options. I explained, nothing that would be new to any of you, that, you know, once you decide you're going to do, say, a separation of a division, that then sets in motion a process of typically 18 to 30 months of what you'd call pre-separation activities, followed by the actual market event — a spin out, an IPO, or a sale. In which case there's usually some kind of lockup period, and then, you know, then comes a cash out period that often would run two or three years.

Bill Anderson

executive
#42

I think folks are putting those numbers together and concluding, oh, that's four or five years. Naturally, starting something doesn't require four or five years. That's probably the point where you actually see the complete cash flows, so to speak. Does that make sense, Sachin?

Sachin Jain

analyst
#43

Got it, very clear. The one thing still left to address is what share of Xarelto comes from Japan and Europe, if you could.

Bill Anderson

executive
#44

Do you have that, Stefan? Percent, percent of Xarelto — that's Japan and Europe.

Stefan Oelrich

executive
#45

So if we look at Europe right now, that's a bit more than EUR 2 billion of the EUR 4.5 billion, and Japan, it's — I need to check that. Just a second, and then I'll give you the correct figure. Bear with me. Sorry about that.

Bill Anderson

executive
#46

Sachin, as you can tell from Stefan, throw any question our way and we’ll have an answer ready in roughly 20 seconds. That alone demonstrates our prowess.

Stefan Oelrich

executive
#47

On occasion, that can extend beyond 50 seconds. So Japan accounts for sales of roughly EUR 400 million, and a bit higher on a constant currency basis.

Bill Anderson

executive
#48

Appreciate it, Sachin.

Sachin Jain

analyst
#49

Thanks. Thanks.

Operator

operator
#50

Our next question is from Vincent Andrews at Morgan Stanley. Your line is open.

Vincent Andrews

analyst
#51

Thank you, and good morning. Rodrigo, I just wanted to ask you a couple of things about your outlook. First, it seems like in the fourth quarter, you don't seem too concerned about the seed business in Brazil and the tough farmer economics down there, and maybe the second crop of corn having fewer corn acres, maybe that going to cover crop or to soy. So what's your level of indifference in Brazil these days between a corn acre and a soy acre? And just on the comments for 2024, it also seems like maybe what you're concerned about is just the corn acres might go down and they may go back to soy. and, you know, maybe you're not going to be able to hold all those acres, given you've had some sort of tough share issues in soy with the, with the trade issues. So if you could just talk about what, what is it that's driving, the 2024 concerns, and in particular, if you're seeing any, any issues on price in the order book?

Rodrigo Santos

executive
#52

Thank you, Vincent. I'll begin with that question, Vincent, since you likely also came across yesterday's USDA report, which lines up quite closely with what we're anticipating for the coming year, correct? So potentially a shift of 4 or 5 million acres away from corn and toward more soybean. As you're aware, corn is our most important crop, it's the one that's most profitable, and our market share in corn is very significant. Any time there's a reduction in corn, that benefits our business. So that's the crucial factor. I still believe that in soybean — we also have information on this — we hold a 45% share within our U.S. business in our trade package. So my feeling is we'll remain very competitive there. But naturally, the shift away from corn isn't ideal for us. Brazil, which aligns closely with what you wrote recently, where you see a possible reduction of Safrinha corn in the second season, and roughly 40 to 50% of those sales land in Q4, but that's already factored into our plan. So I feel the key element in LATAM that will help — if you look back to Q4 of last year, we had a short volume of fungicide due to some supply constraints.

Rodrigo Santos

executive
#53

We've seen a recovery in that area this year, and as I've said on many occasions, our management of channel inventories has been extremely, extremely disciplined, and we're keeping an eye on it. Every incentive and every plan we have in Brazil is tied to sellout rather than selling into the distribution channel. That has helped us a great deal in supporting our Q4. That's why we feel very confident about delivering a strong quarter in Q4. We posted a Q3 in our core business with 9% growth in the core, and we expect Q4 to be strong once again as well. But the dynamics are right, so you're seeing more soybean and less corn for the next season — not only in the U.S. but also in Brazil's second season, as you mentioned. Thank you.

Vincent Andrews

analyst
#54

Thanks.

Operator

operator
#55

Our following question is from Emily Field at Barclays. Please go ahead.

Emily Field

analyst
#56

Hi, thanks for taking my questions. First, on the strategic review — given that a separation of crop science does appear to be on the table, how much could the direction of the litigation affect that? In our investor conversations, a lot of investors have been thinking that, because of the litigation overhang, crop science wouldn't be able to stand on its own as an independent entity. And then a follow-up to that same question: after a very strong slate of wins in the ongoing glyphosate litigation, it does look like a couple of cases have gone against Bayer more recently. Are you changing your litigation strategy at all? How should we think about just how those cases are progressing in the U.S.? Thank you.

Bill Anderson

executive
#57

Sure, those are excellent questions. First, on the strategic analysis regarding the structural options, I'd note that these are precisely the kinds of issues we're wrestling with, correct? These decisions don't take much time to reach — a day is enough to decide — yet you end up owning that decision, in a sense, permanently. And there are plenty of, I'd call them, intriguing dynamics tied to the fundamental questions you'd raise in any transaction, like the ones I laid out, plus matters such as the litigation, and all of these must be factored in. Beyond that, there's not much more I can share, though we are certainly giving it proper consideration. Then, Wolfgang, would you like to address the question about the litigation outlook?

Wolfgang Nickl

executive
#58

Sure thing, Emily. That's a good question — actually, a really good one. First off, nobody should assume we're content to come out on the losing end of gain cases. We're here to win them. That said, we never expected to prevail in every single case. As you can imagine, the other side isn't exactly leading with their weakest cases, and they're not filing them in the easiest jurisdictions either. That said, we've won nine of the last 12. Of the three losses, one was an award of $1 million. I can assure you that doesn't even come close to covering the other side's costs. So it's hardly a strong incentive for them to keep pushing. And the remaining two involved very strong grounds for appeal or for getting through post-trial motions successfully. Our approach — and I won't get into much detail — is really to keep focusing on presenting the science to juries across the various courtrooms. And I want to give you two data points you likely haven't absorbed or come across yet. Just yesterday, the Ninth Circuit Court of Appeals in California made it a permanent injunction, meaning California cannot withdraw Prop 65, with a cancer warning on the label of Roundup in California.

Wolfgang Nickl

executive
#59

That is an extremely powerful indicator, honestly. In fact, it was ruled unconstitutional. It was additionally noted that the science supports the label, as the federal government proposed. The second item I want to flag, which hasn’t received much coverage in the media, is a case in Hawaii — and that one isn’t included among the 12 cases I mentioned — where the judge actually never put the case before the jury, on preemption grounds. So certain jurisdictions in the U.S. hold that federal law preempts state law, and those are 2 more facts I believe you ought to be aware of. Beyond that, I think you’ll appreciate that we continually refine our strategy, though this is probably not the appropriate venue for discussing it — but we are quite nimble here.

Emily Field

analyst
#60

Thanks.

Emily Field

analyst
#61

Happy to have you.

Operator

operator
#62

Joel Jackson from BMO Capital Markets has the next question. Please go ahead.

Joel Jackson

analyst
#63

Morning, everyone. Rodrigo, I believe during your comments you mentioned peers—both they and others—along with your competitors, facing greater stocking problems with crop chemistry as we go into 2024. That came up, I think, while you were going over certain building blocks for Crop Science in 2024. Could you expand on that a bit? Is the point essentially that glyphosate has already destocked—it happened early and it hurt, but that's behind you now—and that you expect glyphosate to beat out the other crop chems, or what exactly were you getting at?

Rodrigo Santos

executive
#64

Okay, let me give a bit of context here, since I brought this up on Q2 and I recall a few of the questions you raised back then. When it comes to glyphosate, our inventory, and our CP business, we keep very tight control over channel inventory. Every plan we build is grounded in sellout or what farmers actually use. We offer no incentives or programs aimed at pushing product into distribution. So each month we track all the inventory sitting in the channel, and we continually adjust our sales so that channel inventories don't run high, out of concern for the health of the business. And on Q2, I noted that generic competitor inventory was present in the market and was affecting the flow of sales, though naturally that got corrected too. For us, this has mattered a great deal since the start of this year in Q2, and I'm confirming it again here on Q3 that... And we watched that unfold. We did see it actually happening in Q3, where we observed the sales. And naturally, when I refer to the market or the competitors, that's based on what I've read in public reports and what was claimed regarding the other companies, correct?

Rodrigo Santos

executive
#65

Let me just reiterate what we're planning here. That matters for 2024 as well. In 2024, growth will come more from volume than from pricing, given what we managed to accomplish over the past two years — partly because our approach to inventory management has been extremely disciplined and has served us very well. So you've got it right.

Joel Jackson

analyst
#66

Thanks. All right, and as a follow-up, Bill—

Bill Anderson

executive
#67

Mm-hmm.

Joel Jackson

analyst
#68

You provided really solid detail on the sorts of things you want to accomplish with Bayer at this point at management levels, and you mentioned bureaucracy weighing, I think, on time and performance. As part of that, you face a very big decision about how you're going to restructure the company. Do you split off crop science? Do you not? You want to move fast, I imagine, on some of your restructuring. How do you balance restructuring and making this company, you know, ideal or optimized, when you may have a huge split coming up, and the right structure might be different if you do split the companies — the structure might be different for a pharma company versus, uh, you know, a pesticides and seed company?

Bill Anderson

executive
#69

Yeah, well, I think the alignment we've reached has been remarkably quick — not only with the board of management, and others here can chime in on this, but really with Bayer's leaders, its people, and the employee representatives. Essentially, everyone is saying: Hey, enough. We don't like losing. We have genuinely dedicated, talented people. We have great technologies. Nobody denies that. Somehow, it doesn't all come together in a way that's as powerful and as impactful as it ought to. And we, we've come together on a system to make things a lot faster and a lot more streamlined. And basically, the people of Bayer are emphatic that, you know, they wanna do this. The leaders of Bayer are emphatic about it, and we're just saying: Hey, whatever financial structure we would end up in, we've gotta do this because we owe it to our customers, we owe it to our shareholders, we owe it to our people to get stuff out of the way and get going. And so we basically, we had a lot of, you know, kind of heart-to-heart discussions over the course of the summer, and again, not just, not just with the people in this room, but with our senior leaders, with our employees, with the supervisory board, and basically everyone said: Hey, we're going.

Bill Anderson

executive
#70

So, the question is — it's a race. We're essentially going to find out just how quickly we can move, since a number of the things we plan to do have been done before. I mean, I gained a lot of experience with this at my last company, and these were things we experimented with and implemented across, you know, four, five, six years. There's no time for that around here. And I'm aware our shareholders don't have time for it either. So we made the decision to go on a very ambitious schedule. We're going to try to break every record when it comes to change, and by the end of 2024 we're going to try to have this new system touching every part of our business, which is lightning fast for a fundamental redo. So then I think we say: hey, is there any reason we wouldn't do this?... We can't come up with one, because we say, well, you know, what if we're going to, I don't know, split off this division or split off that division? Say, "Hey, but right now, if we split something and our cash flow is zero, that's, you know, that's not good enough." So we've got to, we've got to improve, period. And then structural options are further potential ways to unlock value.

Bill Anderson

executive
#71

Still, this is something we have to do. So hopefully that gives you an answer. If you'd like to follow up, I'm glad to do that.

Joel Jackson

analyst
#72

Alright, Bill, that’s good for the moment. Thank you.

Operator

operator
#73

Florent Cespedes from Société Générale has the next question. The line is yours — go ahead.

Florent Cespedes

analyst
#74

Good afternoon, this is Florent Cespedes from Société Générale. Thanks so much for taking my questions. I have two quick ones, please. First, for Bill. To return to what you said regarding the pre-separation activities, and you mentioned 18 to 30 months to prepare a potential separation: could you tell us how independent the different divisions are? If a separation of a consumer were the route taken, it is fair to assume that would be quicker than Crop Science, which is a bigger division. So some color on these potential options would be great. My second question is for Stefan. Stefan, could you elaborate on how you see the trend of the situation in China going forward? Thank you.

Bill Anderson

executive
#75

Thanks, Florent. I'm not certain it would be all that straightforward to say which divisions are more independent or more dependent. What we have at present is a shared backbone, correct? So finance, legal, HR, and IT are all shared functions, more or less common across the board. After that, the divisions each have their own setup. And yes, it's accurate that consumer health and pharma both sit within healthcare, yet their customers differ greatly and their product types are fairly distinct as well. So it isn't so clear-cut. There may be qualitative distinctions, but our sense was that we're roughly within the same time range, whichever option we might choose. And we don't view the timing as something that necessarily blocks doing it. It's simply a factor we must take into account when considering costs and benefits and how much energy would be needed. So hopefully that responds to your question. And then-

Florent Cespedes

analyst
#76

Yeah.

Bill Anderson

executive
#77

Stefan?

Stefan Oelrich

executive
#78

Well, bonjour, Florent. That's a good question about China, clearly, since I think anybody with significant exposure there is having a hard time this year. As a quick reminder, we got off to a rough start in January and February because of the COVID shutdown, and that carried on with the current campaign, which I want to stress once more is aimed at hospitals and not at our industry. But since this affects how hospitals buy, we're seeing that impact strongly this quarter and the one before. So at the moment, what we observe is that activity — promotional activity — is picking back up, not to the level we had previously, but it is getting better step by step. I'd expect to see some improvement on that front as well going into next year. And then there's a second aspect, which is volume-based procurement, and I think it hits companies differently. I'm looking at a slide of the top 10 companies here, and what I'd encourage you to examine is how large each company's exposure is, depending on whether they were part of the first VBPs, which are kind of nearing their conclusion and are now shifting into provincial management, versus the more recent VBPs, namely VBP 5 to 8.

Stefan Oelrich

executive
#79

Bayer is heavily exposed to that latter category, meaning we’re feeling more pressure at the moment than some of our competitors, let’s say. That said, when it comes to innovation, China stays a highly appealing market for launches. We’re looking at the situation—if you set aside the latest 2 quarters—but when I consider how Nubeqa and Corvidia are being taken up, those results are very encouraging in a country such as China, given its potential and its size. So for us, China will remain a very attractive market as we move forward. However, I would expect, because of that specific VBP exposure across VBP 5 to 8, that Bayer will have a next year in which, in China, we won’t see growth. So after a really difficult 2023, what we’re going to see in China is another flattish year.

Florent Cespedes

analyst
#80

Thanks a lot.

Operator

operator
#81

Christian Faitz from Kepler Cheuvreux has the next question. The line is yours.

Christian Faitz

analyst
#82

Yes, thank you. I have one question left, please. Turning back to litigation, could you give us an update on the PCB settlements, and especially on any litigation still pending as of right now? Thank you.

Wolfgang Nickl

executive
#83

Hi Christian. A quick update on PCB. There hasn’t been much change. You’ve likely noticed in the special items that we reached settlements with two states, Virginia and Pennsylvania. A lot of people were worried that this might move closer to the outlier situation in Oregon—which we felt quite confident about—and that didn’t occur. It’s also not true that all the other states have fallen into line. I believe there are three or four states we’re still working with. So we feel fairly confident on that front. As for the personal injury cases, there isn’t much to add. You’re all aware that we lost a few in Washington state. We are appealing those, and we’re awaiting the appeal in the first case, Erickson. But unfortunately, I can’t say much more than that right now, Christian.

Christian Faitz

analyst
#84

Much appreciated, Wolfgang.

Wolfgang Nickl

executive
#85

Glad to have you with us.

Operator

operator
#86

Laurent Favre from BNP has the next question. The line is yours.

Laurent Favre

analyst
#87

Hello, yes. Good afternoon. Bill, I have a question for you regarding the significant restructuring effort that I believe you are referring to, along with what is known as the DSO. When we run a basic benchmarking analysis, it appears that in terms of headcount productivity, you are roughly 15%-20% under your pure play competitors across all three divisions, which could suggest a headcount surplus that is not in the thousands but rather in the tens of thousands. Should we take it that the restructuring you are considering for next year focuses more on structure and the management side, and that afterward you will allow the various businesses to operate with their optimal cost structure? Or are you planning to address the entire cost component before making a decision on structure?

Bill Anderson

executive
#88

Yeah. No, I appreciate the chance to clear that up. So, yeah, we're tackling the core items immediately. I mean, we've already started. So, yeah, at this point it's essentially a whole-company effort, and that's going to stay the case for a while, with our senior leaders collaborating closely alongside employee representatives. And as I said, one illustration is that we're taking another look at our go-to-market model across all three divisions — I mean, that is fundamental. It touches every country where we do business, the roles, the way, not only how the frontline salespeople are organized, but also the people who support them, whether they sit in the country, in regions, or globally, and that's only one illustration. So yeah, what we're describing is a thorough rethink and change across, you know, essentially every role and every activity. And then we're sort of adding the structural question on top of that. But it's not... Yeah. On the first part, regarding the major revitalization, there's no remaining doubt about the if. It's simply a matter of how, you know, how much, how fast, how far can we go? And we're going to go as far as we can, and I think we're confident that there's quite a distance still to cover on it.

Bill Anderson

executive
#89

And then we’ll put the structural questions on top of that. Does that make sense?

Laurent Favre

analyst
#90

Yeah. All right. Thanks a lot.

Bill Anderson

executive
#91

Thanks.

Operator

operator
#92

Our following question is from Steve Byrne at Bank of America. Go right ahead.

Steve Byrne

analyst
#93

Yeah, thanks. Rodrigo, I wanted to ask how interested you are in attaching additional biologics to the corn seed platform — especially the ammonia-producing bacteria. You've got partnerships with Pivot and with Ginkgo. What's your view on that, and do you see it as a means of adding further value to the corn seed business?

Rodrigo Santos

executive
#94

Thanks, Steve. Thanks for asking, and you've hit the nail on the head. When we laid out the vision for regenerative agriculture here, we saw this chance to bring all of those elements together so farmers can produce more while restoring more at the same time, correct? A key piece of that is biologicals, which you brought up, and of course there are other pieces too. We're moving very quickly on digital as well, to help with that, to be more precise. And you pointed out something else that's a very important part of our strategy. We have plenty of collaboration in place. Partnerships are established, and we're pushing further, right? So, another example we, we shared with you not long ago, cover crops, and how we, we're moving that to the next steps as well, into the market. So this will be a big part of, regenerative agriculture. And just to reinforce, taking this chance, your question, to, the, the remarks that Bill made here today about the operating model. What we aim to do with the new operating model, with the DSO that we discussed, is also to unlock the potential for these breakouts and these new opportunities that we have.

Rodrigo Santos

executive
#95

We're considering additional expansion going forward, and you've hit on one of the crucial components we have lined up for the coming years. Thanks, Steve.

Steve Byrne

analyst
#96

Then I have one brief follow-up question for you. In crop chemicals, are you already observing competitive pricing, or is that more of a worry for 2024, since a tougher outlook for certain of your competitors might result in more aggressive pricing — or are you seeing it already?

Rodrigo Santos

executive
#97

It's the second one, Steve. I think you hit the mark with that second one. I still haven't seen pricing set for the upcoming season on crop protection, but it's more the worry that you describe, correct? So when I look at the reports regarding inventories, older inventories in the market, in the channel, you face a more dynamic pricing challenge for the next season. So that's more the second part of your question. You're right.

Steve Byrne

analyst
#98

I appreciate that.

Rodrigo Santos

executive
#99

Thanks.

Operator

operator
#100

Our following question is from Falko Friedrichs at Deutsche Bank. Falko, the floor is yours.

Falko Friedrichs

analyst
#101

Thanks. First off, at a broad level, could you walk us through some of the possible catalysts for better free cash flow in the coming year? And putting together what you've said on today's call, it doesn't seem like EBITDA will improve a great deal next year. So what other levers are available to you that would at least let you post positive free cash flow next year? Then second, as much as you can, could you give us some help with the 2024 financial results? Just so we don't model this entirely incorrectly. Thank you.

Wolfgang Nickl

executive
#102

Sure, Falko — those are all solid questions. As I mentioned before, the goal clearly isn't for us to remain at a zero free cash flow level. There are a handful of items we're actively working on. First, working capital. You'll have noticed that inventory has risen quite substantially across the past two years, which stems from long lead times and inflation; that inventory is still on the books and hopefully will come down at some point. We're placing a very strong emphasis on accounts payable. We've also observed that our average terms compare more favorably with other industry participants, so we're pursuing accounts payables. Then there's another item — and I'm certain you've noticed this — it's purely mechanics. We had a very, very strong year last year in terms of business performance for 2022, and we paid the related incentives during 2023. Now, unfortunately, performance is weaker this year, so next year we'll have a smaller payment. Those are just three examples, plus, naturally, the profitability you brought up. Within the financial result, we gather a few items. Above all, obviously, interest — and I believe you're aware of the market dynamics there.

Wolfgang Nickl

executive
#103

Rates are climbing. We issued a bond in May, June, and then completed a hybrid bond in September, and now you're asking about higher interest rates. Clearly, the goal is to bring net financial debt down, so that higher rate gets applied to a smaller figure. That's something we're extremely, extremely focused on. And, by the way, the majority of our existing debt carries fixed rates. But just quickly, there are other pieces involved, such as fair value assessments and hedging costs, and those are somewhat difficult to forecast. Still, broadly speaking, I'd expect a modest upward trend in interest, since net financial debt isn't declining as fast as we initially anticipated. I hope that's helpful to you, Falko.

Falko Friedrichs

analyst
#104

Yes, and maybe one quick follow-up: would it be fair to assume that the sum you've put aside for litigation settlements will be somewhat lower next year than it is this year? Can you say anything about that yet?

Wolfgang Nickl

executive
#105

That's a tough one to comment on.

Falko Friedrichs

analyst
#106

Alright, thanks.

Wolfgang Nickl

executive
#107

Glad to help.

Operator

operator
#108

Apologies. The final question today is from James Quigley at Morgan Stanley. Your line is open.

James Quigley

analyst
#109

Thanks very much — I have a couple of questions, if I may. First one, on asundexian: during the last quarter you appeared to be running a bit ahead of what people expected, so is 2025 still on track? You've also broadened the clinical trial program to include patients at greater bleeding risk, so how are you thinking about the trial design there, and what might that extra population mean for asundexian's potential peak sales? Second, just to follow up again on the glyphosate litigation: at the close of 2022 the provision stood at roughly $6.5 billion. There have clearly been some unfavorable rulings lately, but could you tell us how much remains in that provision both for the holdouts and for cases still to come? And how much do the recent developments raise the risk that this provision could grow in the near term? Thank you.

Stefan Oelrich

executive
#110

Hi, James. Appreciate the question, and thanks for apparently sharing our excitement about asundexian. So yes, enrollment in our trial is still moving ahead at quite a rapid rate, so that ought to keep our timelines where they are. Ultimately, we will always need to see that the study accrues events. That is what will decide in the end how quickly we can bring it to a close. But we're hoping to be there at some point in 2025, so that we can put this in front of patients in 2026. So that remains on track. Regarding the new study, we felt there was this unmet need that really isn't addressed right now from an evidence standpoint, and that is among patients who aren't eligible for current treatment, even though they ought to be anticoagulated. But the bleeding risk stops physicians from dosing such patients with the existing therapies like Factor Xa. And that's a sizable group. We also believe this lends further weight beyond our case for access, particularly in geographies such as Europe, where we're going to face major hurdles given the quality of existing therapies like Xarelto, and others. We feel this adds a really important data set that ought to be explored given the product's profile.

Stefan Oelrich

executive
#111

Our confidence in asundexian remains very high.

Wolfgang Nickl

executive
#112

Okay, James, so broadly and really pretty quickly here: on the overall reserve, there's just under EUR 7 billion sitting on the balance sheet, and you can assume that 85%-90% of it relates to glyphosate. Giving you a breakdown doesn't really make sense, honestly. I mean, we're applying accounting rules here. Just the fact that there's a reserve on the balance sheet is no license to print checks and send them out. So it's more or less an accounting treatment, and we evaluate that quarter to quarter based on the rules.

James Quigley

analyst
#113

That's great. Thanks a lot.

Wolfgang Nickl

executive
#114

Glad to have you with us.

Operator

operator
#115

Ladies and gentlemen, we ask for your understanding that time constraints require us to end this call at this point. I now return the floor to Dr. Jost Reinhard for some closing remarks.

Jost Reinhard

executive
#116

Thanks so much, Alice, and I really appreciate the questions and the interest. So with that, we'll wrap up today's call, and I hope everyone has a wonderful day.

Operator

operator
#117

That wraps up Bayer AG's investor and analyst conference call for the third quarter of 2023, ladies and gentlemen. We appreciate everyone joining us. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.